abstract |
(57) [Summary]nThe present invention relates to a medical composition comprising a poly (ADP-ribose) glucohydrolase inhibitor, also known as a PARG inhibitor, and for inhibiting or reducing free radical-induced cell energy depletion, cell damage or cell death. To the use of the composition in a medical device. More particularly, the present invention relates to poly (ADP-ribose) glucohydrolase inhibitors, such as glucose derivatives; ligning glycosides; hydrolyzable tannin-containing gallotannins and ellagitannins; adenoside derivatives; acridine derivative-containing 6,9-diamine-2- Ethoxyacridine lactic acid hydrate; tyrolone R10.656 containing tyrolone analogs, a pharmaceutical composition comprising daunomycin or daunorubicin hydrochloride; ellipticine; proflavin; and other PARG inhibitors; and diseases caused by free radical-induced cellular energy depletion Or their use in treating or preventing tissue damage resulting from cell damage or death due to conditions and / or necrosis, apoptosis or a combination thereof. |